Women after menopause due to sex hormones decrease are prone to osteoporosis. However, clinical anti-osteoporosis drugs are imperfect and with some adverse effects. Accordingly, the focus on new drug study was shifted to estrogenic alternative medicine- natural phytoestrogens which includes isoflavones, lignans and coumarins and were found to have a variety of physiological activities with similar chemical structure to 17β-estradiol. Phytoestrogens combined with estrogen receptor have a bidirection regulation in vivo, that is, to show estrogenic or anti-estrogen effect in different conditions and play an important role in prevention and treatment of postmenopausal osteoporosis by multiple mechanisms. Experimental and clinical studies have proved that phytoestrogenic substances， such as genistein, soy isoflavones, and psoralea from angelica, eucommia, and other phytomedicine, have the exact effects on postmenopausal osteoporosis with the considerable development prospect.